Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of $51.00.
Jason Gerberry has given his Buy rating due to a comprehensive assessment of Immunovant’s strategic positioning and the robust pipeline of its next-generation FcRn programs (‘1402). Immunovant’s clear intent to initiate multiple pivotal trials and explore potential indications over the next two years showcases an ambitious growth trajectory. Despite the necessity for additional capital to support these broad R&D initiatives, the company’s current cash reserves and various financing options are seen as sufficient. The stock’s recent underperformance is attributed to a lack of short-term catalysts, but Gerberry believes that the previous strong performance indicates market confidence in the company’s long-term prospects.
Furthermore, the competitive landscape, including upcoming data from a rival’s Phase 1 study, is acknowledged as a potential risk, yet it’s suggested that the full impact on Immunovant’s valuation will require a more comprehensive understanding of the competitor’s clinical profile. Upcoming updates from Immunovant’s own Phase 2 programs in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease are considered significant de-risking events that could positively influence the stock. Gerberry’s Buy recommendation and a price objective of $51 are underpinned by the belief in Immunovant’s promising autoimmune treatment opportunities and additional catalysts anticipated to materialize in the near future.
Gerberry covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, and Teva Pharmaceutical. According to TipRanks, Gerberry has an average return of 2.1% and a 46.75% success rate on recommended stocks.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $48.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Immunovant (IMVT) Company Description:
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Read More on IMVT:
- Immunovant, Inc. Is Worried About This – Should You Be Worried Too?
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
- The biotech stocks to own in 2024, according to Piper Sandler
- Immunovant price target raised to $52 from $47 at Stifel
- Immunovant price target raised to $51 from $49 at BofA
